Materials for the Financial Results Briefing for the Fiscal Year Ending March 2026 | AS ONE CORPORATION (7476) timely disclosure

Worth reading

81Important

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Mixed performance

Direction inferred from the company’s description.

Scale

6.5

% (year-on-year change in revenue for the fiscal year ending March 2027)

Wording

Conditional

How definitive the wording is.

Contents of this document

Financial results presentationFiscal year ended March 2026 (also includes the full-year plan for the fiscal year ending March 2027)13 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Net Sales¥110,698 million+6.7%

Operating profit¥12,838 million+10.7%

Ordinary income¥13,228 million+9.6%

Net income¥9,179 million+11.5%

Selling, general and administrative expenses¥20,627 million

Gross Profit Margin

Rate30.2%

Year-on-year change (points)+0.0% (elsewhere +0.05 Pt)

Operating profit margin

Rate11.6%

Year-on-year change (points)+0.4%

Results for the three months of the current quarterIncludes quarterly revenue by business area, revenue by initiative, and e-commerce sales for 1Q, 2Q, 3Q, and 4Q of the fiscal year ended March 2026. Consolidated revenue was ¥25,637 million in 1Q, ¥25,774 million in 2Q, ¥27,791 million in 3Q, and ¥31,493 million in 4Q.

Full-year earnings forecast

Net Sales

¥117,850 million

Gross profit

¥35,680 million

Operating profit

¥12,900 million

Ordinary income

¥13,350 million

Net income

¥8,970 million

Annual dividend

¥66 per share

What the company explained in this material

Self-assessment against the planThe company's self-assessment against its own plan.

For the fiscal year ended March 2026, revenue, gross profit, operating profit, ordinary income, and net income exceeded the plan. By business area, Industry fell short of the plan.

Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.

Impact of higher sales¥2,100 million
Private-label and imported products¥300 million
Web-only products¥130 million
National-brand products¥-400 million
Large orders¥20 million
Gross margin improvement¥50 million

Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.

Price increases for plastic consumables
Figures20〜30%
FY2026 revision to the medical fee schedule (main component)
Figures+3.09%
Company-operated delivery routes in the Kanto region
Figures4 additional routes and a 40% increase in delivery destinations (forecast)

New initiatives

Construction and opening of a new rental and calibration center
Expansion of SHARE-DB
Upgrade to AXEL 2.0, an AI-powered search engine
Launch of 4-Stock, a supply chain inventory visibility service
Launch of Mare’s, a procurement support tool for medical institutions
Consolidation and expansion of the Kanto logistics hub at Smart DC
Expansion into laboratory design and interior construction management services

Key KPIsA metric the company considers important as a management benchmark.

EC sales¥38,259 million
Year on year against the same period last year+12.8%
Product Range1,400 10,000 products
Year on year against the same period last year+12.9%
Number of ocean connections643 companies
Year on year against the same period last year+49.2%
Number of registered Wave users23,965 people
Year on year against the same period last year+13.9%
ROE13.3 %
Year on year against the same period last year+0.7%

Segment results

Laboratory
Net Sales69,387
Industry
Net Sales23,798
Medical
Net Sales16,925

Medium-term management plan targets

ROE

TargetAt least 13.0%

Actual results13.3%

Financial targets

ROE

TargetAt least 13.0%

Actual results13.3%

Market Size / Share

Approximately 7,000 small and medium-sized hospitals and 1,000 large hospitals. Proprietary products account for 34% of sales.

Capital expenditures

¥2,352 million forecast for the fiscal year ending March 2027

Annual Dividend

Annual dividend per share¥66 per share

Payout ratio

50.0% or higher (dividend policy); 50.6% actual for the fiscal year ended March 2026

Acquisition of treasury shares

Buyback limitApproximately ¥1 billion

Contents of this document
Item	Details
Document type	Financial results presentation
Fiscal Period Covered	Fiscal year ended March 2026 (also includes the full-year plan for the fiscal year ending March 2027)
Net Sales	¥110,698 million (YoY +6.7%)
Operating profit	¥12,838 million (YoY +10.7%)
Ordinary income	¥13,228 million (YoY +9.6%)
Net income	¥9,179 million (YoY +11.5%)
Gross Profit Margin	Rate 30.2% / Year-on-year change (points) +0.0% (elsewhere +0.05 Pt)
Operating profit margin	Rate 11.6% / Year-on-year change (points) +0.4%
Selling, general and administrative expenses	¥20,627 million
Results for the three months of the current quarter	Includes quarterly revenue by business area, revenue by initiative, and e-commerce sales for 1Q, 2Q, 3Q, and 4Q of the fiscal year ended March 2026. Consolidated revenue was ¥25,637 million in 1Q, ¥25,774 million in 2Q, ¥27,791 million in 3Q, and ¥31,493 million in 4Q.
Full-year earnings forecast	Net Sales ¥117,850 million / Gross profit ¥35,680 million / Operating profit ¥12,900 million / Ordinary income ¥13,350 million / Net income ¥8,970 million / Annual dividend ¥66 per share
Self-assessment against the plan	For the fiscal year ended March 2026, revenue, gross profit, operating profit, ordinary income, and net income exceeded the plan. By business area, Industry fell short of the plan.
Segment results	Segment Laboratory / Net Sales ¥69,387 million / yoy_pct ¥8.6 million, Segment Industry / Net Sales ¥23,798 million / yoy_pct ¥7.3 million, Segment Medical / Net Sales ¥16,925 million / yoy_pct ¥-1 million
Breakdown of Factors Affecting the Change	Factors Impact of higher sales / Amount ¥2,100 million, Factors Private-label and imported products / Amount ¥300 million, Factors Web-only products / Amount ¥130 million, Factors National-brand products / Amount ¥-400 million, Factors Large orders / Amount ¥20 million, Factors Gross margin improvement / Amount ¥50 million
Key KPIs	Indicator name EC sales / Value ¥38,259 million / Year on year against the same period last year ¥12.8 million, Indicator name Product Range / Value 1,400 10,000 products / Year on year against the same period last year 12.9 10,000 products, Indicator name Number of ocean connections / Value 643 companies / Year on year against the same period last year 49.2 companies, Indicator name Number of registered Wave users / Value 23,965 people / Year on year against the same period last year 13.9 people, Indicator name ROE / Value 13.3 % / Year on year against the same period last year 0.7 %
Assumptions Underlying the Business Outlook	Item Price increases for plastic consumables / Figures 20〜30%, Item FY2026 revision to the medical fee schedule (main component) / Figures +3.09%, Item Company-operated delivery routes in the Kanto region / Figures 4 additional routes and a 40% increase in delivery destinations (forecast)
Medium-term management plan targets	ROE Target At least 13.0% / Actual results 13.3%
Financial targets	ROE Target At least 13.0% / Actual results 13.3%
Annual Dividend	Annual dividend per share ¥66 per share / Interim and Year-End Breakdown Not disclosed
Payout ratio	50.0% or higher (dividend policy); 50.6% actual for the fiscal year ended March 2026
Acquisition of treasury shares	Buyback limit Approximately ¥1 billion / Number of Shares Not disclosed / Period Not disclosed
Capital expenditures	¥2,352 million (forecast for the fiscal year ending March 2027)
Market Size / Share	Approximately 7,000 small and medium-sized hospitals and 1,000 large hospitals. Proprietary products account for 34% of sales.
New initiatives	Construction and opening of a new rental and calibration center, Expansion of SHARE-DB, Upgrade to AXEL 2.0, an AI-powered search engine, Launch of 4-Stock, a supply chain inventory visibility service, Launch of Mare’s, a procurement support tool for medical institutions, Consolidation and expansion of the Kanto logistics hub at Smart DC, Expansion into laboratory design and interior construction management services

Items this document does not state (7)

Progress against full-year forecastUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

For the fiscal year ended March 2026, results benefited from e-commerce growth, the recovery in corporate purchasing activity, lower freight and warehouse operating costs resulting from logistics initiatives, and expense control. For the fiscal year ending March 2027, the company expects costs to increase in connection with the new rental and calibration center, the expansion of Smart DC, and investments in logistics, IT, and human resources. The impact of the situation in the Middle East on procurement and sales has not been incorporated into the earnings forecast because it is difficult to calculate reasonably.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.